CRISPR: can gene-editing help nature cope with climate change?
Posted: November 30, 2017 at 8:44 pm
The debate about Johnny Depps casting as Grindelwald in the Fantastic Beasts and Where To Find Them franchise rages on. A quick recap: Depp was cast as Grindelwald a few years ago, but it was kept under wraps, as his casting was part of a big twist at the end of the first film.
But last summer, just before Fantastic Beasts was released, Amber Heard, his now ex-wife, accused Depp of domestic abuse. Videos of Depp throwing bottles and glasses and shouting at Heard, photos of Heards bruises, and text exchanges between Heard and Depps manager, all made their way into the press. The couple later released a joint statement saying neither party had lied for financial gain and that there wasnever any intent of physical or emotional harm.
The latest developments come as the press for the second Fantastic Beasts film, The Crimes of Grindelwald kicks into gear. The title, and images of Depp in character, reignited a debate over whether someone accused of domestic abuse should be given such a high-profile role, especially in a progressive childrens franchise. Depp has continuously denied all allegations since the divorce as salacious false stories.
On Tuesday, in an interview with Entertainment Weekly, Fantastic Beasts director David Yates explicitly defended Depps character, calling the concerns of audiences a dead issue. Yates attempted to positively contrast the allegations against Depps with those made against Harvey Weinstein and Kevin Spacey.
Honestly, theres an issue at the moment where theres a lot of people being accused of things, he said.[But] with Johnny, it seems to me there was one person who took a pop at him and claimed something.
Its very different [to instances] where there are multiple accusers over many years that need to be examined and we need to reflect on our industry that allows that to roll on year in and year out. Johnny isnt in that category in any shape or form. So to me, it doesnt bear any more analysis. It's a dead issue.
Yates also seemed to find it relevant that hehas had no direct experience of Depp being abusive towards him. He added: I can only tell you about the man I see every day: Hes full of decency and kindness, and thats all I see. Whatever accusation was out there doesnt tally with the kind of human being Ive been working with.
Its an interesting departure from Yatess previous take on the issue, which emphasised Depps talent over his private actions, separating art from artist. The whole principal of casting the movie was go with the best actor, he said last year. In this business, its a weird old business. Youre brilliant one week, people are saying odd things the next, you go up and down. But no one takes away your pure talent. Johnny Depp is a real artist.
Its possible that after the widely commended decisions from studios and directors to have both Harvey Wenstein and Kevin Spacey removed from their cinematic projects, Yates has felt the need to change tack. Instead of saying that the personal actions of an actor are irrelevant to their professional roles an argument that Hollywood and the public seem to have moved beyond he tries to separate Depp from those men by emphasising the differences in the actions themselves.
In 2016, J K Rowling simply said of Depps casting,Im delighted. Hes done incredible things with that character, again ensuring the focus stayed solely on talent rather than Depps character as a colleague or friend.
Those comments cause some controversy, and in the days after, she tweeted a couple of cryptic quotes seemingly referencing the situation. First, Those only who can bear the truth will hear it. - Arthur Helps. Then, Arguments cannot be answered by personal abuse; there is no logic in slander, and falsehood, in the long run, defeats itself - R G Ingersoll. When a fan messaged her to say, We know you'd never support abuse, Rowling, whose first husband Jorge Arantes has admitted to acting abusively,replied Thank you x. Its impossible to say from these quotes what her position actually is. Is the truth she references a belief that Depp is not really an abuser? Or is she hinting that she would like to re-cast the role, or condemn Depps casting, but is contractually unable to?
Since then, shes been silent on the issue. Although Rowlings actual thoughts on the situation are unclear, supporters of Depp see these cryptic tweets, the casting, and her general lack of condemnation of Depp, as evidence that she supports him. If you look up the hashtags #JohnnyDeppIsInnocent and #JohnnyDeppIsMyGrindelwald, J K Rowling immediately appears as a related person and related search term, as so many Depp supporters are mentioning the two in the same breath either thanking J K Rowling for her support, or using her name to argue that Depp must be innocent if even J K Rowling herself thinks so. Some have even used the hashtag #JohnnyDeppIsJKRowlingsGrindelwald.
Domestic violence is by nature a more difficult crime to discuss that serial instances of documented workplace sexual harassment it happens at home, with few or no witness, to people in complex existing romantic relationships.
In Amber Heards own words, When it happens in your home, behind closed doors, with someone you love, its not as straightforward as if a stranger did this. Clearly, Hollywood still finds allegations of domestic violence easier to swallow than workplace harassment.
See the article here:
CRISPR: can gene-editing help nature cope with climate change?
- What's the Latest in CRISPR Gene-Editing Technology? - Technology Networks - March 12th, 2024
- In vivo genome-wide CRISPR screening identifies CITED2 as a driver of prostate cancer bone metastasis | Oncogene - Nature.com - March 12th, 2024
- Investigating the mechanisms underlying resistance to chemoterapy and to CRISPR-Cas9 in cancer cell lines ... - Nature.com - March 12th, 2024
- Here's Why CRISPR Therapeutics Stock Climbed 34% in February - The Motley Fool - March 12th, 2024
- SXSW Panel Recap: The First CRISPR Foods Have Arrived - Austin Chronicle - March 12th, 2024
- CRISPR-Cas systems: Overview, innovations and applications in human ... - March 4th, 2024
- CRISPR Therapeutics Stock Has 32% Upside, According to 1 Wall Street Analyst - The Motley Fool - March 4th, 2024
- Missed Out on CRISPR Therapeutics? My Best Gene-Editing Stock to Buy and Hold - The Motley Fool - March 4th, 2024
- MEGA-CRISPR tool gives a power boost to cancer-fighting cells - Nature.com - February 23rd, 2024
- 3 Biotech Stocks to Buy That Have CRISPR-Like Breakthrough Potential - InvestorPlace - February 23rd, 2024
- CRISPR 'will provide cures for genetic diseases that were incurable before,' says renowned biochemist Virginijus iknys - Livescience.com - February 23rd, 2024
- Opinion: The Promise and Challenges of CRISPR-Based Treatments - BioSpace - February 23rd, 2024
- There's Reason For Concern Over CRISPR Therapeutics AG's (NASDAQ:CRSP) Massive 26% Price Jump - Simply Wall St - February 23rd, 2024
- Move over, CRISPR: RNA-editing therapies pick up steam - Nature.com - February 23rd, 2024
- If You Invested $10000 in CRISPR Therapeutics in 2019, This Is How Much You Would Have Today - The Motley Fool - February 23rd, 2024
- CRISPR Therapeutics Joins Rank Of Stocks With 95-Plus Composite Rating - Investor's Business Daily - February 23rd, 2024
- CRISPR Therapeutics (NASDAQ:CRSP) Hits New 12-Month High on Better-Than-Expected Earnings - AmericanBankingNEWS - February 23rd, 2024
- CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results - GlobeNewswire - February 23rd, 2024
- CRISPR Therapeutics AG (CRSP) Moves 6.9% Higher: Will This Strength Last? - Yahoo Finance - February 23rd, 2024
- Advancements in RNA for HIV Treatment: CRISPR Cas9, mRNA Therapeutics, and Next-Generation Sequencing ... - Medriva - February 23rd, 2024
- Intellia Therapeutics Charges Ahead: A Glimpse into the Future of CRISPR-Based Therapies - BNN Breaking - February 23rd, 2024
- The FDA Approved The First CRISPR-Based Therapy. What's Next? - Science Friday - February 5th, 2024
- Using CRISPR technology, researchers succeed in growing tomatoes that consume less water without compromising yield - Phys.org - February 5th, 2024
- CRISPR-Cas9 gene-editing tool repairs defective T cells to treat rare hereditary disease - News-Medical.Net - February 5th, 2024
- New CRISPR Technology Increases Recognition of Cancer Cells by the Immune System - Inside Precision Medicine - February 5th, 2024
- Is CRISPR Therapeutics a Buy in the New Bull Market? - The Motley Fool - February 5th, 2024
- Stocks Flashing Renewed Technical Strength: CRISPR Therapeutics - Investor's Business Daily - February 5th, 2024
- AI at Davos, new CRISPR therapies and health tech's bad marketing - Marketplace - January 20th, 2024
- FDA expands use of newly approved CRISPR therapy - Axios - January 20th, 2024
- CRISPR-based therapy receives expanded approval for beta thalassemia - STAT - January 20th, 2024
- CRISPR Therapeutics And Vertex's CRISPR Breakthrough: How And Why They Got There First - Scrip - January 20th, 2024
- Pharmalittle: We're reading about a CRISPR approval, selling meds directly to patients, and more - STAT - January 20th, 2024
- Here's Why CRISPR Therapeutics Stock Rose 54% Last Year - The Motley Fool - January 20th, 2024
- Vertex's CRISPR Gene Therapy Lands Another FDA Nod in a Rare Blood Disease - MedCity News - January 20th, 2024
- Groundbreaking CRISPR/Cas9-based Genome Editing Therapy Secured the Second FDA Approval - geneonline - January 20th, 2024
- What Does It Mean for Investors if CRISPR Therapeutics Gets Bought Out in 2024? - The Motley Fool - January 20th, 2024
- First FDA-approved CRISPR-based gene therapy cleared for 2nd indication - LabPulse - January 20th, 2024
- CRISPR Therapeutics Announces U.S. Food and Drug Administration (FDA) Approval of CASGEVY ... - GlobeNewswire - January 20th, 2024
- CRISPR Gene Editing And Its Role In Hematology | TheHealthSite.com - TheHealthSite - January 20th, 2024
- Doudna institute hatches plan to 'cure hundreds of diseases' left behind by CRISPR revolution - STAT - January 11th, 2024
- Discover the recent progress of nonviral delivery carriers for CRISPR/Cas9 systems - News-Medical.Net - January 11th, 2024
- How CRISPR could yield the next blockbuster crop - Nature.com - January 11th, 2024
- Weight-loss drugs, malaria vaccines and more: CRISPR innovations headline the science breakthroughs of 2023 - Genetic Literacy Project - January 11th, 2024
- CRISPR Therapeutics Highlights Strategic Priorities and 2024 Outlook - GlobeNewswire - January 11th, 2024
- CRISPR Therapeutics AG (CRSP) 42nd Annual J.P. Morgan Healthcare Conference (Transcript) - Seeking Alpha - January 11th, 2024
- CRISPR to be used to genetically modify crops - FoodNavigator.com - January 11th, 2024
- Casgevy approval unlikely to be followed up by another CRISPR drug in near future - BioPharma-Reporter.com - January 11th, 2024
- Vertex Announces Approval of First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY, for the Treatment of Sickle Cell ... - Business Wire - January 11th, 2024
- The Science Behind CRISPR: Germline Genome Editing and Its Applications - Medriva - January 11th, 2024
- Here's Why 2024 Could Be a Big Year for CRISPR Therapeutics - The Motley Fool - January 11th, 2024
- Revolutionizing acne treatment with CRISPR technology - Labiotech.eu - January 11th, 2024
- What Is CRISPR Gene Editing and How Does It Work? - December 25th, 2023
- This first CRISPR treatment is just the beginning. Heres what's next - Fast Company - December 25th, 2023
- The Age of Crispr Medicine Is Here - WIRED - December 25th, 2023
- 6 Words That Explain Why CRISPR Stock Isn't Soaring Despite the Recent FDA Approval for Its Gene-Editing Therapy - Yahoo Finance - December 25th, 2023
- Crispr Therapeutics Medical Chief Morrow to Resign - The Wall Street Journal - December 25th, 2023
- Crispr Therapeutics chief medical officer is resigning - MarketWatch - December 25th, 2023
- 3 Reasons to Buy CRISPR Therapeutics Stock Like There's No Tomorrow - Yahoo Finance - December 25th, 2023
- CAR T Therapy May Cause Rare Cancer & How CRISPR Could Be The Solution - Forbes - December 25th, 2023
- CRSP Stock Alert: CRISPR Therapeutics Is Losing Its Medical Chief - InvestorPlace - December 25th, 2023
- With the promise of saving millions of lives, CRISPR medicine is born - EL PAS USA - December 25th, 2023
- Casgevy: the world's first CRISPR therapy - Epigram - December 25th, 2023
- The Basics of CRISPR Gene Editing - Cleveland Clinic Health Essentials - November 27th, 2023
- Mechanism and Applications of CRISPR/Cas-9-Mediated Genome Editing - November 27th, 2023
- What is CRISPR gene editing, and how does it work? - The Conversation - October 16th, 2023
- What is CRISPR/Cas9? - PMC - National Center for Biotechnology Information - October 16th, 2023
- CRISPR, 10 Years On: Learning to Rewrite the Code of Life - April 26th, 2023
- What Is CRISPR, and Why Is It So Important? - Scientific American - March 23rd, 2023
- Global CRISPR Technology Market Is Projected To Grow At A 22% Rate Through The Forecast Period - EIN News - March 14th, 2023
- What is CRISPR and why is it controversial? | CNN - February 2nd, 2023
- CRISPR | Description, Technology, Uses, & Ethical Concerns - February 2nd, 2023
- In vivo CRISPR screening reveals nutrient signaling processes ... - PubMed - December 12th, 2022
- What is CRISPR? | New Scientist - October 16th, 2022
- CRISPR-Cas9 Structures and Mechanisms - PubMed - October 16th, 2022
- A CRISPR cure for HIV? Gene-editing technology may be able stop viral replication in its tracks and wipe out infections - Genetic Literacy Project - October 16th, 2022
- Editas Medicine Presents Preclinical Data on EDIT-103 for Rhodopsin-associated Autosomal Dominant Retinitis Pigmentosa at the European Society of Gene... - October 16th, 2022
- More Foods Will Be Gene-Edited Than You Think - The Epoch Times - October 16th, 2022
- What is CRISPR? - MD Anderson Cancer Center - September 21st, 2022
- CRISPR infusion eliminates swelling in those with rare genetic disease - Science - September 21st, 2022
- Crispr Therapeutics becomes the latest biotech to open in the Seaport - The Boston Globe - September 21st, 2022